Mayo Clinic Laboratory and Pathology Research Roundup: Jan. 14

By Kelley Luedke • January 14, 2019

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts

Most patients with esophageal adenocarcinoma (EAC) present with de novo tumors. Although this could be due to inadequate screening strategies, the precise reason for this observation is not clear. Mayo Clinic researchers compared survival of patients with prevalent EAC with and without synchronous Barrett esophagus (BE) with intestinal metaplasia (IM) at the time of EAC diagnosis. Clinical data were studied using Cox proportional hazards regression to evaluate the effect of synchronous BE-IM on EAC survival independent of age, sex, TNM stage, and tumor location. Researchers analyzed data from a cohort of patients with EAC from the Mayo Clinic and a multicenter cohort from the United Kingdom. Two types of EAC can be characterized based on the presence or absence of BE. These findings could increase the understanding of the etiology of EAC and be used in management and prognosis of patients. The study was published in Gastroenterology.

Published to PubMed This Week

• • • • • Pathological, Imaging and Genetic Characteristics Support the Existence of Distinct TDP-43 Types in Non-FTLD Brains
          Acta Neuropathologica
          
        • Molecular Signatures of Multiple Myeloma Progression through Single Cell RNA-Seq
          Blood Cancer Journal
          
        • Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk from Intermediate- and High-Risk Prostate Cancer
          Mayo Clinic Proceedings
          
        • Cost Efficacy of α-Galactosidase A Enzyme Screening for Fabry Disease
          Mayo Clinic Proceedings
        • Cancer Susceptibility Gene Mutations in Type I and II Endometrial Cancer
          Gynecologic Oncology
          
        • Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety
          Antimicrobial Agents and Chemotherapy
          
        • Pro-fibrotic Effects of IL-17A and Elevated IL-17RA in IPF and RA-ILD Support a Direct Role for IL-17A/IL-17RA in Human Fibrotic Interstitial Lung Disease
          American Journal of Physiology-Lung Cellular and Molecular Physiology
        • Cigarette Smoking Is Associated with Adverse Pathological Response and Increased Disease Recurrence amongst Patients with Muscle-Invasive Bladder Cancer Treated with Cisplatin-Based Neoadjuvant Chemotherapy and Radical Cystectomy: A Single-Centre Experience
          BJU International
          
        • Proceedings from the Ice Hockey Summit III: Action on Concussion
          Current Sports Medicine Reports
        • Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series
          American Journal of Hospice and Palliative Medicine
        • Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with the JAK2V617F Mutation
          Haematologica
          
        • Using Germline Variants to Estimate Glioma and Subtype Risks
          Neuro-Oncology
          
        • A Moldy Application of MALDI: MALDI-ToF Mass Spectrometry for Fungal Identification
          Journal of Fungi

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.